LYZZ Capital is a global healthcare-dedicated venture capital and private equity firm that invests in talents, assets, and technologies worldwide. Their strategy emphasizes unmet medical needs and large market potential, particularly in China, with a focus on Series A and Series B funding rounds.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (50% of deals).
Portfolio
2
Fund Size
$600M
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
2 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Neurelis, Inc. | Series D | $114M | Mar 2021 |
 Qpex Biopharma | Series A | $33M | Oct 2018 |
Top Co-Investors
NEA (New Enterprise Associates)1 shared
Adams Street1 shared
Cormorant Asset Management1 shared
HBM Healthcare Investment1 shared
Last updated: 28 April 2026